Depomed Company Profile (NASDAQ:DEPO)

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (?)
Ratings Breakdown: 2 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $23.50 (23.68% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016MizuhoReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Janney Montgomery ScottReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Leerink SwannReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Piper Jaffray Cos.Lower Price TargetOverweight$23.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Depomed (NASDAQ:DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016$0.26N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.04)$0.03$41.50 million$51.49 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.08)($0.01)$38.03 million$67.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$0.10($0.01)$53.57 million$76.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$1.05$1.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2011$0.06$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Depomed (NASDAQ:DEPO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.14)($0.14)($0.14)
Q3 20161$0.04$0.04$0.04
Q4 20161$0.09$0.09$0.09
Q1 20171$0.10$0.10$0.10
Q2 20171$0.09$0.09$0.09
Q3 20171$0.20$0.20$0.20
Q4 20171$0.23$0.23$0.23
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Depomed (NASDAQ:DEPO)
DateHeadline
07/23/16 03:30 PMDepomed, Inc. (NASDAQ:DEPO) Expected To Post Sales Of $924 - Investor Newswire
07/22/16 03:31 PMNoninvasive VNS Promising in Chronic Migraine Prevention
07/21/16 07:03 AMStock Moving Lower for the Month; Investor Update on Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
07/19/16 08:53 PMDepomed Inc versus The Medicines Company Head to Head Compare - CML News
07/19/16 03:40 PMDepomed, Inc. (NASDAQ:DEPO) Wall Street Analyst Recommendation Outlook - TGP
07/19/16 03:40 PMANI Pharmaceuticals Inc versus Depomed Inc Head to Head Compare - CML News
07/19/16 03:40 PMMedtronic PLC (NYSE:MDT) & Depomed Inc (NASDAQ:DEPO) are Hot Stocks - Money News (press release)
07/19/16 03:40 PMDepomed : Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent
07/19/16 03:40 PMAnalyst Rating Fluctuations to Observe: Depomed, Inc. (NASDAQ:DEPO) , Keryx Biopharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/18/16 01:24 PMBRIEF-Depomed says Patent Board Denies IPR of NUCYNTA Patent - * Depomed announces patent trial and appeal board denial of inter partes review of Nucynta patent
07/18/16 12:35 PM1:35 pm DepoMed announces the PTAB declined to institute the Inter Partes Review petition filed by Rosellini Scientific with respect to U.S. Patent No. 7,994,364 with respect to all patent claims subject of the petition -
07/18/16 12:34 PMDepomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent - [PR Newswire] - NEWARK, Calif., July 18, 2016 /PRNewswire/ -- Depomed, Inc. (DEPO) today announced the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute the Inter Partes Review (IPR) petition filed by Rosellini Scientific, LLC with respect to U.S. Patent No. 7,994,364 (the "'364 Patent") with respect to all patent claims subject of the petition. The '364 Patent is listed for the company's NUCYNTA® (tapentadol) and NUCYNTA® ER (tapentadol extended release tablets) products in the FDA's Orange Book. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to the timing of a decision in the ANDA litigation related to its NUCYNTA and NUCYNTA ER products, as well as other risks detailed in the company's Securities and Exchange Commission filings, including the company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. There can be no assurance of a positive outcome in such litigation, or other assurance that actual results will be as expected or anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
07/16/16 07:00 AMDepomed, Inc. (NASDAQ:DEPO) Yearly Sales Target At $997.235 - Investor Newswire
07/15/16 02:36 PMWere Analysts Bullish Depomed Inc (NASDAQ:DEPO) This Week? - Consumer Eagle
07/14/16 03:51 PMDepomed Inc versus Horizon Pharma plc Head to Head Compare - CML News
07/14/16 05:49 AMDepomed, Inc. (NASDAQ:DEPO) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 03:43 PMEarnings Surprise in Focus: Depomed, Inc. (NASDAQ:DEPO) - Investor Newswire
07/13/16 03:43 PMPenn Capital Management Co INC Increased * Depomed INC (NASDAQ:DEPO) by $6.07 Million as Shares Declined - Press Telegraph
07/13/16 03:43 PMTwo Movers within Analysts Observation: Gilead Sciences, Inc. (NASDAQ:GILD) , Depomed, Inc. (NASDAQ:DEPO) - Street Updates
07/13/16 03:43 PMUBS Downgrades Depomed Inc to Neutral - Trade Calls
07/13/16 03:43 PMAnalysts and Technical Snapshot on Depomed Inc (NASDAQ:DEPO) - Street Report
07/12/16 08:57 PMShares Losing Ground for the Month; Investor Alert on Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
07/11/16 03:38 PMStock Performance Rundown on: Depomed, Inc. (NASDAQ:DEPO) - Press Telegraph
07/09/16 03:23 PMUBS Downgrades Depomed Inc (DEPO) - Smarter Analyst
07/09/16 07:03 AMShares Finishing Down for the Week Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
07/09/16 07:03 AMDepomed, Inc. (NASDAQ:DEPO) Expected To Post Sales Of $997.235 - Investor Newswire
07/09/16 07:03 AMTwo Buzzers within Analysts Radar: Humana Inc. (NYSE:HUM) , Depomed, Inc. (NASDAQ:DEPO) - Street Updates
07/09/16 07:03 AMDepomed Inc. (DEPO) Drops 8.71% on July 07 - Equities.com
07/08/16 06:51 PMDepomed Releases Lazanda® 300 mcg Dose for Treatment of Breakthrough Cancer Pain - [at noodls] - New Dose Provides Physicians Additional Titration Flexibility to Help Effectively Manage BTPc NEWARK, Calif., July 7, 2016 /PRNewswire/ -- Depomed today announced that Lazanda (fentanyl) nasal spray, CII, ...
07/08/16 08:44 AMUBS Steps To Sidelines on Depomed, Citing Limited Upside; Stock Sinks ~6%
07/07/16 08:47 PMAnalyst Update: Depomed Inc, Charles Schwab Corp, and Freeport-McMoRan Inc
07/07/16 03:37 PMHeightened Volatility Check on: Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
07/07/16 03:37 PMShares Dropping Lower in Session: Depomed, Inc. (NASDAQ:DEPO) - Telanagana Press
07/07/16 03:37 PMDepomed Inc (NASDAQ:DEPO)'s Company Shares Increased 0.59% After High Volatility - Press Telegraph
07/07/16 03:37 PMUBS Downgrades DepoMed Inc (DEPO) to Neutral - StreetInsider.com
07/07/16 03:24 PMDepomed Downgraded On Weakness In Base Business, Stock Run-Up -
07/07/16 10:17 AMDepoMed downgraded by UBS -
07/07/16 08:29 AMUBS Downgrades DepoMed Inc (DEPO) to Neutral
07/06/16 03:41 PMCan Depomed, Inc. (NASDAQ:DEPO) Improve on the Earnings Front? - Engelwood Daily
07/06/16 08:21 AMStock Tracking Down This Month; Investor Alert on Depomed, Inc. (NASDAQ:DEPO) - Engelwood Daily
07/06/16 08:21 AMDepomed, Inc. (NASDAQ:DEPO) Current Analyst Ratings - Fiscal Standard
07/06/16 07:21 AMDepomed to Present at the Cantor Fitzgerald Healthcare Conference - [at noodls] - NEWARK, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced its participation at Cantor Fitzgerald's 2 Annual Healthcare Conference in New York, New York. Depomed's President ...
07/05/16 08:18 AMCan Depomed, Inc. (NASDAQ:DEPO) Surprise Analysts this Quarter? - Investor Newswire
07/05/16 08:18 AMShare Performance Recap for: Depomed, Inc. (NASDAQ:DEPO) - Press Telegraph
07/05/16 08:18 AMNew Broker Ratings For Depomed, Inc. (NASDAQ:DEPO) - FTSE News
07/02/16 03:36 PMDepomed Inc. (DEPO) is Trading Higher on Unusual Volume for June 30
07/01/16 03:35 PMHow Analysts Feel About Depomed Inc (NASDAQ:DEPO)? - Press Telegraph
06/30/16 08:57 PMRecently Issued Stock Ratings For Depomed, Inc. (NASDAQ:DEPO) - Fiscal Standard
06/29/16 03:34 PMPenn Capital Management Co INC Increased * Depomed INC (NASDAQ:DEPO) by $6.07 Million as Shares Declined - Engelwood Daily
06/29/16 03:34 PMDepomed Inc. (DEPO) Jumps 5.95% on June 28 - Equities.com

Social

About Depomed

Depomed logoDepomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company's products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: DEPO
  • CUSIP: 24990810
Key Metrics:
  • Previous Close: $19.00
  • 50 Day Moving Average: $19.47
  • 200 Day Moving Average: $17.11
  • P/E Ratio: N/A
  • P/E Growth: 0.89
  • Market Cap: $1.16B
  • Beta: 1.22
  • Current Year EPS Consensus Estimate: $1.20 EPS
  • Next Year EPS Consensus Estimate: $1.60 EPS
Additional Links:
Depomed (NASDAQ:DEPO) Chart for Sunday, July, 24, 2016